What's breaking now, across thousands of outlets.
A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
Ticks are especially abundant this summer. However, there are several ways to mitigate the risks associated with them, says Tiina Elvisto, associate professor of plant ecology at Tallinn University.
Dubai: A health awareness programme held in Dubai has highlighted the importance of preventive healthcare, regular medical check-ups and early intervention, particularly for people whose busy work…
Scientists linked early-life stress experience in mice to long-term stress hypersensitivity within the brain’s dopaminergic circuitry, providing a mechanism by which early-life stress increases risk…
Silence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial.
Journalists can apply for AHF Nigeria’s two-month HIV and TB media reporting project to promote ethical, solutions-focused reporting on these diseases.
A Tenax Therapeutics drug designed to treat a type of heart failure associated with high blood pressure in the lungs failed in a closely watched study.
